Phase III Study of ASP2151 in Herpes Simplex Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

468

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 27, 2015

Conditions

Herpes Simplex

Interventions

DRUG

ASP2151

200 mg once daily

DRUG

ASP2151 placebo

once daily

Trial Locations (3)

Sapporo

Yokohama

Nakano-ku

All Listed Sponsors

lead

Maruho Co., Ltd.

INDUSTRY

NCT01959295 - Phase III Study of ASP2151 in Herpes Simplex Patients | Biotech Hunter | Biotech Hunter